The aroylhydrazone INHHQ prevents memory impairment induced by Alzheimer's-linked amyloid- β oligomers in mice

Anna de Falco, Grasielle Kincheski, Elena Atrián-Blasco, Christelle Hureau, Sergio Ferreira, Nicolás Rey

► To cite this version:

Anna de Falco, Grasielle Kincheski, Elena Atrián-Blasco, Christelle Hureau, Sergio Ferreira, et al.. The aroylhydrazone INHHQ prevents memory impairment induced by Alzheimer's-linked amyloid- β oligomers in mice. Behavioural Pharmacology, 2020, 31 (8), pp.738-747. 10.1097/FBP.0000000000000578 . hal-03412868

HAL Id: hal-03412868

<https://hal.science/hal-03412868>

Submitted on 15 Nov 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**The aroylhydrazone INHHQ prevents memory impairment induced by
Alzheimer's-linked A β oligomers in mice**

INHHQ prevents A β -induced memory impairment

(short title to be used as “running head”)

Anna DE FALCO^a, Grasielle C. KINCHESKI^{b,c}, Elena ATRIÁN-BLASCO^d,

Christelle HUREAU^d, Sergio T. FERREIRA^{b,c*}, Nicolás A. REY^{a*}

^aDepartment of Chemistry, Pontifical Catholic University of Rio de Janeiro, Brazil;

^bInstitute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Brazil;

^cInstitute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Brazil;

^dLCC-CNRS, Université de Toulouse, CNRS, Toulouse, France.

*Joint corresponding authors:

Nicolás A. Rey, Department of Chemistry, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, RJ 22453-900, Brazil; nicoarey@puc-rio.br; or Sergio T. Ferreira, Institute of Biophysics Carlos Chagas Filho and Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21944-590, Brazil; ferreira@bioqmed.ufrj.br.

Author contributions

In vivo experiments were designed by ADF, GCK, STF and NAR, conducted and analyzed by ADF and GCK. ROS generation experiments were designed by EAB and CH, conducted and analyzed by EAB. The manuscript was initially written by ADF, GCK, EAB and CH; and revised by STF and NAR.

Notes

The Pontifical Catholic University of Rio de Janeiro holds granted patents in the United States of America (US 10,189,811 B2 and US 10,316,019 B2) related to the compound INHHQ, under the unified title “Method for Preparing the Anhydrous Crystalline Form of Isoniazid-Derived Hydrazone, Thus Produced Crystalline Polymorph of the Anhydrous Form, Use Thereof for the Treatment of Alzheimer's Disease, Parkinsonism and Other Neurodegenerative Disorders, and Pharmaceutical Composition”, in which NAR is the main inventor.

Part of the results described in this manuscript was extracted from Anna De Falco's PhD thesis work, and the author has clearly authorized the use of the data for the purpose of publication.

ABSTRACT

Converging evidence indicates that neurotoxicity and memory impairment in Alzheimer's disease (AD) are induced by brain accumulation of soluble amyloid- β oligomers (A β O_s). Physiological metals are poorly distributed and concentrated in the senile plaques typical of AD, where they may be coordinated to the amyloid- β peptide (A β). Indeed, zinc and copper increase A β oligomerization and toxicity. Metal-Protein Attenuating Compounds (MPACs) represent a class of agents proposed for AD treatment, as they reduce abnormal interactions of metal ions with A β , inhibit A β oligomerization and prevent deleterious redox reactions in the brain. The present work investigates the protective action of an isoniazid-derived aroylhydrazone, INHHQ, on A β O-induced memory impairment. Systemic administration of a single dose of INHHQ (1 mg kg⁻¹) prevented both short- and long-term memory impairment caused by A β O_s in mice. *In vitro* studies showed that INHHQ prevents Cu(A β)-catalyzed production of reactive oxygen species. Although the mechanism of protection by INHHQ is not yet fully understood at a molecular level, **the results reported herein certainly** point to the value of aroylhydrazones as promising neuroprotective agents in AD and related disorders.

Keywords

Alzheimer's disease, A β oligomers, memory impairment, hydrazones, MPACs, ROS.

Abbreviations

A β , amyloid- β peptide; A β O_s, A β ₁₋₄₂ oligomers; HMW-A β O_s, high molecular weight A β O_s; INHHQ, 8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone; i.p., intraperitoneal(ly); LMW-A β O_s, low molecular weight A β O_s; LTM, long-term memory; MPAC, metal-protein attenuating compound; NOR, novel object recognition; OF, open field; ROS, reactive oxygen species; STM, short-term memory.

INTRODUCTION

Alzheimer's disease (AD) is the most prevalent form of dementia in the elderly. Recent reports indicate that 35 million people are currently affected by AD, with a predicted increase to 50 million cases by 2030 (Alzheimer's Association, 2018). Presence of extracellular senile plaques formed by fibrillar aggregates of the amyloid- β peptide ($A\beta$) is a major pathological feature of AD (Mayeux and Stern, 2012). In addition to insoluble fibrils, $A\beta$ forms soluble oligomers ranging from dimers to 24-mers and even larger species. Robust evidence accumulated in the past two decades supports the hypothesis that $A\beta$ oligomers ($A\beta$ Os) are largely responsible for synaptic toxicity and memory impairment in AD (Ferreira and Klein, 2011, Mucke and Selkoe, 2012, Ferreira et al., 2015, Selkoe and Hardy, 2016). Previous studies have shown that endogenous metal ions mediate $A\beta$ oligomerization and potentiate its toxicity (Bush et al., 1994, Lovell et al., 1998, Miura et al., 2000). It has been proposed that deregulation of metal homeostasis in AD promotes $A\beta$ aggregation and leads to the accumulation of redox-active biometals within or in the vicinity of neurons, producing reactive oxygen species (ROS) and causing oxidative damage and neurodegeneration (Bush, 2013).

Metal-Protein Attenuating Compounds (MPACs) could represent an interesting therapeutic approach to inhibit metal-induced $A\beta$ oligomerization and to decrease metal-mediated toxicity (Scott and Orvig, 2009, Sampson et al., 2012, Savelieff et al., 2018). The current MPACs repertoire is mainly based on the well-known 8-hydroxyquinoline (8-HQ) scaffold, being Clioquinol (CQ) the first example proposed (Mancino et al., 2009). Unfortunately, different studies report a correlation between treatment with CQ and the occurrence of subacute myelo-optic neuropathy, which encouraged the search for less toxic analogues (Sampson et al., 2012). PBT2, a CQ derivative, demonstrated promising therapeutic potential for management of AD, decreasing both soluble and insoluble $A\beta$ levels, and improving cognitive performance in a transgenic mouse model of the disease (Adlard et al., 2008). However, despite positive phase II trial results (Lannfelt et al., 2008), a recent 12-month double-blinded study reported a lack of significant difference between placebo and 250 mg day⁻¹ PBT2 treatment in biochemical and cognitive analyses (Villemagne et al., 2017).

Several other 8-HQ derivatives have been studied in recent years, showing chelating capacity towards biometals and inhibition of Cu²⁺/Zn²⁺-induced $A\beta$ aggregation. Most of these agents presented low cytotoxicity and protective effects against oxidative stress (Gomes et al., 2014, Ryan et al., 2015, Yang et al., 2018). Multitargeted and hybrid compounds have also attracted attention regarding their potential suitability for the treatment of neurological disorders (Unzeta et al., 2016, Savelieff et al., 2018). Many of them, yet, still rely on the 8-HQ pharmacophore (Kupersmidt et al., 2012, Salkovic-Petrisic et al., 2015, Wang et al., 2015, Fu et al., 2016, Prati et al., 2016, Su et al., 2016).

Aroylhydrazones present both a recognized metal chelating ability and a broad spectrum of pharmacological applications (Savini et al., 2004, Silva et al., 2005, Vicini et al., 2006, Kajal et al., 2014). This prompted us to synthesize and characterize a hybrid compound combining the 8-HQ scaffold with an aroylhydrazone moiety, 8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone (INHHQ; Figure 1), as an MPAC for the treatment of AD (de Freitas et al., 2013). INHHQ blocks the interactions of Zn^{2+} and Cu^{2+} with A β *in vitro* (Hauser-Davis et al., 2015). The compound crosses the blood-brain barrier, as suggested initially by *in silico* studies and proved subsequently by detection of INHHQ in the brains of intraperitoneally (i.p.) injected Wistar rats (Cukierman et al., 2017). Moreover, *in vivo* acute toxicity assays indicated that INHHQ was nontoxic up to 200 mg kg⁻¹ (Hauser-Davis et al., 2015, Cukierman et al., 2017). Herein, the ability of INHHQ to prevent memory impairment in an AD mouse model was investigated using the Novel Object Recognition (NOR) task, which represents, to the best of our knowledge, the first study of this type performed for an aroylhydrazone. Additionally, INHHQ's activity on Cu(A β)-mediated ROS production was evaluated as one of the possible mechanisms underlying its protective action.

MATERIALS AND METHODS

Animals

Three-month-old male Swiss mice, weighing 35 ± 4 g, were used. Animals were housed in groups of five per cage with *ad libitum* access to food and water under a 12 h light/dark cycle with controlled temperature and humidity. **Independent groups of animals were used for each behavioral test, unless otherwise specified.** All procedures were approved by the Institutional Animal Care and Use Committee of the Federal University of Rio de Janeiro (protocol 001/2019).

INHHQ

INHHQ was synthesized as reported by De Freitas *et al.* (2013).

Preparation of A β Os

A β oligomers consisting of a mixture of High Molecular Weight (HMW) and Low Molecular Weight (LMW) species were prepared weekly from synthetic A β ₁₋₄₂ (American Peptide; Sunnyvale, CA) as previously described (Lambert et al., 1998). All preparations were routinely characterized by size-exclusion chromatography as already reported (Jürgensen et al., 2011, Sebollela et al., 2012, Figueiredo et al., 2013), and, occasionally, by western immunoblots (De Felice et al., 2007, De Felice et al., 2008, Jürgensen et al., 2011, Sebollela et al., 2012). A β Os were kept at the temperature of 4 °C and used within 48 h of preparation.

Treatment with INHHQ

Mice were treated with INHHQ (or vehicle) *via* i.p. injection of 10 mL kg⁻¹ saline solution containing 10% DMSO (Sigma-Aldrich; Germany) and the desired doses of INHHQ.

Intracerebroventricular injections

Intracerebroventricular (i.c.v.) infusion of A β Os was performed as described (Figueiredo et al., 2013, Ledo et al., 2013, Lourenco et al., 2013, Ledo et al., 2016). Animals were anesthetized with 2.5% isoflurane (Cristalia; Brazil) using a vaporizer system and were gently restrained only during the injection (total time ~ 7 min). For administration of a final volume of 3 μ L vehicle or A β Os (10 pmol A β , expressed as monomers), a 2.5 mm length needle was inserted unilaterally 1 mm to the right of the midline point equidistant from both eyes and 1 mm posterior to a line drawn through the anterior base of the eyes, as previously reported (Laursen and Belknap, 1986, Figueiredo et al., 2013). Mice showing any signs of misplaced injections or brain hemorrhage were excluded from further analysis.

Elevated plus-maze

The apparatus used consists of four wooden arms with black flooring arranged in a cross shape. Two arms are enclosed by black walls (30 x 5 x 15 cm) opposite to two open arms (30 x 5 cm), and the apparatus is set up 50 cm above the room floor. The test lasted 5 min and was performed in a room with fluorescent lighting, with intensity set at 44 lux. **Independent groups of animals were tested 1 or 4 h after administration of different doses of INHHQ.** The animals were placed on the central platform of the raised cross maze with the head facing one of the closed arms and the behavioral parameters recorded were: frequency of entry into the open arms and closed arms of the labyrinth, and length of permanence of the animals in the open arms and in the closed arms of the labyrinth. These data were used to calculate the percentage of open arms entries (OAE) and the percentage of time spent in open arms (OAT) using the following equations (Eq.1 and Eq.2):

$$\%OAE = \frac{\text{open entries}}{\text{Total entries}} \times 100, \quad (\text{Eq.1})$$

$$\%OAT = \frac{\text{open time}}{\text{Total time}} \times 100. \quad (\text{Eq.2})$$

General exploratory behavior was represented by the frequency of enclosed arm entries (EAE). After each test session, the maze was cleaned with a 10% solution of alcohol in water (Lister, 1990, Rodgers and Dalvi, 1997).

Open field

The animals were placed at the center of an OF, where their spontaneous activity was recorded during 5 min. Tests were performed in independent groups of animals 1 or 4 h after administration of three different doses of INHHQ (namely, 1, 10 or 25 mg kg⁻¹) or vehicle. The apparatus consists of a wooden arena with black floor (30 x 30 cm) and 40 cm high walls. The luminous intensity at the center of the OF was 50 lux. The total distance travelled and total time spent on a virtual center square (10 x 10 cm) were automatically quantified using Any-maze® video-tracking system (Stoelting Inc.; Kiel, WI). As before, the arena was cleaned with 10% ethanol between trials.

Novel Object Recognition test

Mice were first habituated for 5 min in an open field arena as the one described in the previous section. The novel object recognition (NOR) test was performed by first allowing mice to freely explore the OF containing two identical objects for 5 min (training phase). The exploration times for each object were measured by an observer and expressed as the total exploration time, and percentage of exploration time for novel and familiar object were calculated.

Test sessions were performed 1, 4 or 24 h after administration of three different doses of INHHQ (1, 10 or 25 mg kg⁻¹) or vehicle. For the sessions completed 1 and 24 h after INHHQ administration, the same set of animals was used. An independent group was employed in the NOR test performed 4 h after administration of INHHQ. Mice tested in the test sessions, animals were individually reintroduced in the same OF, and one of the objects presented during the training phase was replaced by a novel object. The exploration times for each object were measured by an observer and expressed both as the discrimination index and as percentages of the total exploration time. The discrimination index, or D index, is defined as the difference in exploration time between the novel and the familiar objects divided by the total time spent exploring the two objects in the discrimination phase (Eq. 3):

$$D \text{ index} = \frac{(\text{Novel object exploration time} - \text{Familiar object exploration time})}{\text{Total exploration time}} \quad (\text{Eq.3})$$

The arena was cleaned with 20% ethanol between trials in order to eliminate olfactory cues. All OF sessions were performed during the light phase of the cycle (7 am – 5 pm). Tests were performed, in a first stage, using four groups (N= 8-16 mice per group) of mice that received i.p. injections of saline containing 10% (V/V) DMSO with four different INHHQ doses, namely 0, 1, 10, and 25 mg kg⁻¹. NOR was evaluated at the timepoints 1, 4 or 24 h after INHHQ injection. A similar experiment was performed using four additional groups (N= 9-10 mice per group) of mice that received an i.p. injection of saline containing 10% (V/V) DMSO with or without 1 mg kg⁻¹ INHHQ. After 1 hour, these mice received i.c.v.

infusions of A β Os (10 pmol) or vehicle. NOR was assessed 24 or 48 h after A β Os infusion, first allowing the animals to freely explore an OF containing two identical objects for 5 min, followed by the retention tests: 1 h (for evaluation of short-term memory, STM) or 24 h (for evaluation of long-term memory, LTM) after training, as described above. Seven days after the first test, a second training was performed, and the NOR task was repeated with different objects from those used in the first two phases of the experiment. In this case, the same mice were tested at the three different times.

Ascorbate consumption

Consumption of ascorbate, which mirrors the production of hydrogen peroxide (Alies et al., 2013), was determined by measuring absorbance at 265 nm ($\epsilon = 14,500 \text{ M}^{-1} \text{ cm}^{-1}$) with a baseline correction at 800 nm as a function of time. A β_{1-16} (aa sequence: DAEFRHDSGYEVHHQK, $M = 1955.1 \text{ g mol}^{-1}$, purchased from GeneCust – Dudelange, Luxembourg) was used as it constitutes a good model peptide for the redox activity of full-length A β (Lu et al., 2010, Hureau, 2012, Conte-Daban et al., 2018). Conditions in the cuvette were as follows: [Cu(II)] = 9 μM , [Zn(II)] = 0 or 10 μM , [A β_{1-16}] = 0 or 10 μM , [INHHQ] = 0, 10 or 50 μM , [ascorbate] = 100 μM , HEPES = 50 mM, pH 7.4. The solutions were stirred at 800 rpm and kept at 25 °C. The rate of ascorbate oxidation was calculated by considering the slope of the variation in ascorbate concentration during the first 60 s after INHHQ addition. Reference values in presence of Cu(A β) or Cu,Zn(A β) were measured at an equivalent ascorbate concentration ($\sim 65 \mu\text{M}$), corresponding to $A = 1.0$.

Statistics

Mice that did not explore the objects used in the NOR test in either the training or test phases, animals showing any signs of sickness or stress, or, as already pointed out previously, mice showing misplaced i.c.v. injection or brain hemorrhage were excluded from further analysis. Additional details of mice exclusion are provided as Supplementary Digital Content.

All values are expressed as mean $\pm$ SEM. Normal distribution of data was checked using the D'Agostino & Pearson *omnibus* normality test. All data were evaluated using Grubbs' outlier test. Data were analyzed by one- or two-way ANOVA followed by the Bonferroni *post hoc* test. Data from the NOR task were additionally analyzed using a one-sample *t*-test comparing the percentage of exploration of the novel object against the chance value of 50%, as previously described (Figueiredo et al., 2013, Ledo et al., 2013, Lourenco et al., 2013, Ledo et al., 2016, Lourenco et al., 2019). The significance level in all analyses was $p < 0.05$. All tests were performed using the GraphPad Software (version 5.00 for Windows).

RESULTS

Statistical analyses showed that INHHQ doses up to 25 mg kg⁻¹ did not cause fear or anxiety as assessed by the elevated plus-maze test and by the open field test either 1 or 4 h after administration of the compound (Figure 2 a-h). There was a trend of decreased locomotor activity and increased percentage of time spent at the center of the arena 4 h after treatment with 25 mg kg⁻¹ INHHQ (Figure 2 g and h, respectively). However, the decrease in locomotor activity was statistically significant (Bonferroni's multiple comparison test with $P=0.0101$) only when the 25 mg kg⁻¹ INHHQ group was compared to the other dose groups, 1 and 10 mg kg⁻¹ ($t=2.914$, and $t=3.088$, respectively). The difference was not statistically significant when the comparison was performed with the group treated only with vehicle ($t=1.535$). The complete statistical analysis is provided as Supplementary Digital Content (Table SDC1).

Results from the NOR test (Figure 2 i-q) showed that INHHQ, at doses of 10 and 25 mg kg⁻¹, but not at 1 mg kg⁻¹, caused acute memory impairment detected when the test was done 1 hour after i.p. administration (Figure 2 i) [no INHHQ: $t=3.582$; 1 mg kg⁻¹ INHHQ: $t=3.229$; 10 mg kg⁻¹ INHHQ: $t=0.1085$; 25 mg kg⁻¹ INHHQ: $t=0.4865$]. Nonetheless, performance in the NOR test was normal 4 or 24 h after administration of up to 25 mg kg⁻¹ INHHQ (Figure 2 j and k), indicating that memory impairment induced by the highest drug doses was transient, as confirmed through the D index analysis (Figure 2 m and n). Although there was a trend of decrease in D index 1 h after treatment with 10 and 25 mg kg⁻¹ INHHQ doses (Figure 2 l) [$F(3,33)=3.213$, $P=0.0354$], this difference was not statistically significant when the comparison was made with the group treated only with vehicle [$t=0.2737$ and $t=0.2448$, respectively]. A statistically significant difference was detected in total exploration time 4 h after INHHQ injection (Figure 2 p) (Bonferroni's multiple comparison test with $P=0.0073$) only when the 25 mg kg⁻¹ INHHQ group was compared to the other dose-receiving groups, 1 and 10 mg kg⁻¹ ($t=3.100$ and $t=2.937$, respectively). On the other hand, total exploration time showed no statistical differences amongst tested doses and the control group at 1, 4 or 24 h after INHHQ injection (Figure 2 o-q). The complete statistical analysis can be found in supplementary Tables SDC1 and SDC2.

Figure 3 illustrates the outcomes of the NOR test performed 24 h, 48 h or 7 days after i.c.v. infusion of A β Os. Systemic treatment with a single dose of 1 mg kg⁻¹ INHHQ prevented both STM and LTM impairment induced by A β Os, and memory protection was maintained for up to one week. Although in LTM analysis the differences between exploration times for novel and familiar objects did not yield statistically significant differences in the discrimination index (Figure 3 b) [$F(1,35)$ interaction = 11.74, $F(1,35)$ INHHQ factor = 3.161 and $F(1,35)$ A β Os factor = 3.659], in all NOR tests mice treated with INHHQ showed a clear preference for the novel object, expressed by percentages of exploration higher than the chance value of 50% (Figure 3 d-f) [24 h test: $t(9)=6.301$, $P=0.0001$; 48 h test: $t(8)=2.882$, $P=0.0181$; 7 days test: $t(9)=8.428$, $P<0.0001$]. Full statistical analysis results of these data are available

as Tables SDC2 and SDC3. A difference in exploration time was detected during the training phase in the NOR tests when 25 mg kg⁻¹ INHHQ were administrated 4 h before the assay (see Supplementary Digital Content, Tables SDC4 and SDC5, as well as Figure SDC1), indicating that this higher dose may affect animal behavior.

Additionally, we have verified that INHHQ possesses the *in vitro* ability to decrease ascorbate consumption induced by Cu(A β): in the presence of 1 equivalent of this compound, the rate of ascorbate consumption was reduced by ~ 30% (Figure 4 a and b). A further increase in INHHQ concentration up to 5 equivalents led to an even larger (~ 50%) reduction. The presence of Zn²⁺ ions slightly increased Cu(A β)-induced ROS production (Figure 4 a and c), but did not alter the effectiveness of INHHQ.

DISCUSSION

In 2013, we implemented i.c.v. infusion of A β ₁₋₄₂ oligomers in Swiss mice as a model to directly investigate A β Os' deleterious impact *in vivo* (Figueiredo *et al.*, 2013). This model has been shown to recapitulate key neuropathological features and memory deficits of Alzheimer's disease. In the present work, three different doses of the potentially neuroprotective hydrazone INHHQ, namely 1, 10 and 25 mg kg⁻¹, which are well below the nontoxic dosage of 200 mg kg⁻¹ previously reported in rats (Hauser-Davis *et al.*, 2015, Cukierman *et al.*, 2017), were administered i.p. to some of the Swiss mice groups studied.

INHHQ doses of 10 or 25 mg kg⁻¹ induced transient memory impairment. This effect may be due to temporary brain dyshomeostasis of metals that play relevant roles in synaptic functions in response to the mild chelation therapy with INHHQ. We note, however, that memory performance returned to normal 4 hours after administration of the compound, suggesting self-equilibration of brain metal homeostasis. We further note that no lethality or sign of toxicity was observed at any INHHQ dose tested.

Based on the results obtained, we chose the safe working dose of 1 mg kg⁻¹ INHHQ to assess the protective effect of this compound against memory impairment induced by A β Os. Thus, INHHQ was administered i.p. 1 h before (i.e., focusing on a preventative approach) the i.c.v. infusion of A β Os. As previously reported (Figueiredo *et al.*, 2013, Ledo *et al.*, 2013, Lourenco *et al.*, 2013, Brito-Moreira *et al.*, 2017, Lourenco *et al.*, 2019), A β O-infused mice presented memory impairment detectable as early as 24 h post-infusion of A β Os and this deleterious effect persists for at least 7 days.

Given its good acute toxicity profile (Hauser-Davis *et al.*, 2015, Cukierman *et al.*, 2017), our results suggest that INHHQ holds potential to combat memory impairment in AD, warranting further *in vivo* investigations of its efficacy in additional AD models, *e.g.*, investigating its beneficial actions after onset of memory deficits. It is worth noting that Adlard *et al.* reported that two other MPACs, namely PBT2 and CQ, improved learning and memory in APP^{swe}PS1 Δ E9 (APP/PS1) mice, a transgenic model

272 of familial AD (Adlard et al., 2008). Tests with PBT2 or CQ were performed with 30 or 10 mg kg⁻¹ per
273 day doses administered during 11 or 35 days, respectively (Adlard et al., 2008). In more recent studies,
274 Kupersmidt *et al.* (2012) reported that the multifunctional chelator M30 attenuated anxiety and memory
275 deficits in APP/PS1 mice. M30 (1 or 5 mg kg⁻¹) was administered by gavage four times a week beginning
276 at 3 months of age and continued for 9 months (Kupersmidt et al., 2012). We found that treatment with
277 a single dose of 1 mg kg⁻¹ INHHQ prevents both short- and long-term memory impairments in an
278 experimental model of sporadic AD.

279 The efficacy of INHHQ in preventing memory impairment can further be compared to that of
280 memantine, a well-known NMDA receptor blocker and the only drug introduced in clinical practice for
281 AD treatment during the past two decades. We previously showed that administration of memantine (10
282 mg kg⁻¹) by gavage for 7 days prevents memory impairment induced by HMW-A β O_s, but not by LMW-
283 A β O_s (Figueiredo et al., 2013). Our current findings demonstrate that a single i.p. administration of a 10-
284 fold lower dose of INHHQ prevents memory impairment induced by A β O preparations containing both
285 HMW and LMW A β oligomers. Therefore, the results presented herein suggest that INHHQ is much more
286 effective than memantine in preventing memory impairment induced by AD-related A β oligomers.

287 In order to investigate a possible, albeit probably not the only one, mechanism of protection by
288 INHHQ, we evaluated the compound's activity on Cu(A β)-mediated ROS production. Oxidative stress
289 constitutes a hallmark of several amyloidogenic diseases, including AD, but its link to disease progression
290 is only partly understood (Atrián-Blasco et al., 2018b, Cheignon et al., 2018). A β O_s have been shown to
291 induce marked neuronal oxidative stress (De Felice et al., 2007, Decker et al., 2010, Saraiva et al., 2010).
292 The production of reactive oxygen species (ROS) by Cu(A β) complexes, together with brain metal ion
293 imbalance, may be one of the mechanisms underlying oxidative stress and neuroinflammation in AD.
294 Thus, targeting Cu(A β)-mediated ROS production appears as an important goal in metal-based therapy of
295 AD. Investigation of the effect of INHHQ on Cu(A β ₁₋₁₆)-induced ROS production was performed using
296 a well-validated ascorbate consumption assay (Jiang et al., 2010, Cheignon et al., 2016, Atrián-Blasco et
297 al., 2018a). The high affinity metal binding site of A β ₁₋₄₂ is entirely comprised between amino acid
298 residues 1 and 16. Therefore, A β ₁₋₁₆ is frequently used as a model for the metal coordination properties
299 and ROS generation ability of the full-length peptide (Conte-Daban et al., 2018). Ascorbate consumption
300 mirrors the production of ROS: a faster consumption rate corresponds to an increased ROS generation
301 (Alies et al., 2013). While the rate of ascorbate consumption is lower when copper is coordinated to A β
302 in comparison to the free metal, contribution to ROS production by the Cu(A β) complex is not negligible
303 (Atrián-Blasco et al., 2018a).

The results obtained agree with previous data which determined that up to 5 equivalents of INHHQ are needed to effectively compete with A β ₁₋₄₀ for binding of Cu²⁺ (Hauser-Davis et al., 2015). Moreover, zinc is not an obstacle to the inhibition of ROS production by INHHQ, in contrast to previously reported metal chelators (Conte-Daban et al., 2016, Conte-Daban et al., 2018). This constitutes an important feature of INHHQ, considering the ubiquitous presence of zinc in the synaptic cleft (Atrián-Blasco et al., 2017).

Although the mechanisms of pathogenesis in AD are still incompletely known, a large body of evidence implicates A β in cellular toxicity. The hypothesis that A β neurotoxicity is explained by the neuronal impact of soluble A β oligomers has gained considerable support in the past two decades (Ferreira and Klein, 2011, Cline et al., 2018). Converging evidence also supports a link between biometals, A β oligomerization and toxicity. In this scenario, MPACs could be a promising avenue in the search for new anti-AD drug candidates. While other concurrent modes of action, such as those involving suppression of metal-mediated aggregation, as well as the inherent antioxidant potential of phenol-containing compounds cannot be ruled out, our results suggest that the mechanism of protection by INHHQ may involve a reduction in Cu(A β)-induced ROS production, even in the presence of competing Zn²⁺ ions.

CONCLUSIONS

The “state-of-the-art” in Metal-Protein Attenuating Compounds research includes a variety of substances, with the most representative ones belonging to the 8-HQ derivatives type. Although the hybrid compound INHHQ contains the 8-HQ group as well, we have shown that the aroylhydrazone moiety is the actual metal-binding unit in it (Cukierman et al., 2018). Therefore, results presented here on the prevention of memory impairment induced by A β oligomers in mice suggest that aroylhydrazones warrant attention as a potential new class of MPACs. In fact, INHHQ displays more potent activity than memantine in the animal model of sporadic AD we have studied. In pursuing the molecular basis behind this interesting activity, we demonstrated that INHHQ is capable of inhibiting the production of reactive oxygen species catalyzed by Cu(A β). The investigation of other potential INHHQ mechanisms of action is underway.

Acknowledgements

This work was supported by National Institute for Translational Neuroscience/Brazil (to STF) and by the Brazilian agencies Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, to NAR and STF). ADF was recipient of a fellowship from CNPq. GCK was recipient of a post-doctoral fellowship from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). CH and EAB thank the European Research Council (ERC) project StG-638712 (aLzINK) for financial support.

- Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M et al. (2008). Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial A β . *Neuron* 59(1):43-55. doi: 10.1016/j.neuron.2008.06.018.
- Alies B, Sasaki I, Proux O, Sayen S, Guillon E, Faller P et al. (2013). Zn impacts Cu coordination to amyloid- β , the Alzheimer's peptide, but not the ROS production and the associated cell toxicity. *Chem Commun (Camb)* 49(12):1214-1216. doi: 10.1039/c2cc38236a.
- Alzheimer's Association (2018). 2018 Alzheimer's disease facts and figures. *Alzheimer's & Dementia* 14(3):367-429. doi: <https://doi.org/10.1016/j.jalz.2018.02.001>.
- Atrián-Blasco E, Conte-Daban A, Hureau C (2017). Mutual interference of Cu and Zn ions in Alzheimer's disease: perspectives at the molecular level. *Dalton Trans* 46(38):12750-12759. doi: 10.1039/c7dt01344b.
- Atrián-Blasco E, Del Barrio M, Faller P, Hureau C (2018a). Ascorbate Oxidation by Cu(Amyloid- β) Complexes: Determination of the Intrinsic Rate as a Function of Alterations in the Peptide Sequence Revealing Key Residues for Reactive Oxygen Species Production. *Anal Chem* 90(9):5909-5915. doi: 10.1021/acs.analchem.8b00740.
- Atrián-Blasco E, Gonzalez P, Santoro A, Alies B, Faller P, Hureau C (2018b). Cu and Zn coordination to amyloid peptides: From fascinating chemistry to debated pathological relevance. *Coordination Chemistry Reviews* 371:38-55. doi: <https://doi.org/10.1016/j.ccr.2018.04.007>.
- Brito-Moreira J, Paula-Lima AC, Bomfim TR, Oliveira FB, Sepúlveda FJ, De Mello FG et al. (2011). A β oligomers induce glutamate release from hippocampal neurons. *Curr Alzheimer Res* 8(5):552-562.
- Brito-Moreira J, Lourenco MV, Oliveira MM, Ribeiro FC, Ledo JH, Diniz LP et al. (2017). Interaction of amyloid- β (A β) oligomers with neurexin 2 α and neuroligin 1 mediates synapse damage and memory loss in mice. *J Biol Chem* 292(18):7327-7337. doi: 10.1074/jbc.M116.761189.
- Bush AI (2013). The metal theory of Alzheimer's disease. *J Alzheimers Dis* 33 Suppl 1:S277-281. doi: 10.3233/JAD-2012-129011.
- Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF et al. (1994). Rapid induction of Alzheimer A beta amyloid formation by zinc. *Science* 265(5177):1464-1467.
- Cheignon C, Collin F, Faller P, Hureau C (2016). Is ascorbate Dr Jekyll or Mr Hyde in the Cu(A β) mediated oxidative stress linked to Alzheimer's disease? *Dalton Trans* 45(32):12627-12631. doi: 10.1039/c6dt01979j.
- Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F (2018). Oxidative stress and the amyloid beta peptide in Alzheimer's disease. *Redox Biol* 14:450-464. doi: 10.1016/j.redox.2017.10.014.
- Cline EN, Bicca MA, Viola KL, Klein WL (2018). The Amyloid- β Oligomer Hypothesis: Beginning of the Third Decade. *J Alzheimers Dis* 64(s1):S567-S610. doi: 10.3233/JAD-179941.
- Conte-Daban A, Day A, Faller P, Hureau C (2016). How Zn can impede Cu detoxification by chelating agents in Alzheimer's disease: a proof-of-concept study. *Dalton Trans* 45(39):15671-15678. doi: 10.1039/c6dt02308h.
- Conte-Daban A, Beyler M, Tripier R, Hureau C (2018). Kinetics Are Crucial When Targeting Copper Ions to Fight Alzheimer's Disease: An Illustration with Azamacrocyclic Ligands. *Chemistry* 24(33):8447-8452. doi: 10.1002/chem.201801520.
- Cukierman DS, Accardo E, Gomes RG, De Falco A, Miotto MC, Freitas MCR et al. (2018). Aroylhydrazones constitute a promising class of 'metal-protein attenuating compounds' for the treatment of Alzheimer's disease: a proof-of-concept based on the study of the interactions between zinc(II) and pyridine-2-carboxaldehyde isonicotinoyl hydrazone. *J Biol Inorg Chem* 23(8):1227-1241. doi: 10.1007/s00775-018-1606-0.
- Cukierman DS, Pinheiro AB, Castiñeiras-Filho SL, da Silva AS, Miotto MC, De Falco A et al. (2017). A moderate metal-binding hydrazone meets the criteria for a bioinorganic approach towards Parkinson's disease: Therapeutic potential, blood-brain barrier crossing evaluation and preliminary toxicological studies. *J Inorg Biochem* 170:160-168. doi: 10.1016/j.jinorgbio.2017.02.020.

390 De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST et al. (2007). Abeta oligomers
 391 induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is
 392 blocked by the Alzheimer drug memantine. *J Biol Chem* 282(15):11590-11601. doi:
 393 10.1074/jbc.M607483200.

394 De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP et al. (2009). Protection of
 395 synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta
 396 oligomers. *Proc Natl Acad Sci U S A* 106(6):1971-1976. doi: 10.1073/pnas.0809158106.

397 De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN et al. (2008). Alzheimer's disease-
 398 type neuronal tau hyperphosphorylation induced by A beta oligomers. *Neurobiol Aging* 29(9):1334-1347.
 399 doi: 10.1016/j.neurobiolaging.2007.02.029.

400 de Freitas LV, da Silva CC, Ellena J, Costa LA, Rey NA (2013). Structural and vibrational study of 8-
 401 hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone--a potential metal-protein attenuating
 402 compound (MPAC) for the treatment of Alzheimer's disease. *Spectrochim Acta A Mol Biomol Spectrosc*
 403 116:41-48. doi: 10.1016/j.saa.2013.06.105.

404 Decker H, Jürgensen S, Adrover MF, Brito-Moreira J, Bomfim TR, Klein WL et al. (2010). N-methyl-D-
 405 aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid- β peptide oligomers.
 406 *J Neurochem* 115(6):1520-1529. doi: 10.1111/j.1471-4159.2010.07058.x.

407 Ferreira ST, Klein WL (2011). The A β oligomer hypothesis for synapse failure and memory loss in
 408 Alzheimer's disease. *Neurobiol Learn Mem* 96(4):529-543. doi: 10.1016/j.nlm.2011.08.003.

409 Ferreira ST, Lourenco MV, Oliveira MM, De Felice FG (2015). Soluble amyloid- β oligomers as
 410 synaptotoxins leading to cognitive impairment in Alzheimer's disease. *Front Cell Neurosci* 9:191. doi:
 411 10.3389/fncel.2015.00191.

412 Figueiredo CP, Clarke JR, Ledo JH, Ribeiro FC, Costa CV, Melo HM et al. (2013). Memantine rescues
 413 transient cognitive impairment caused by high-molecular-weight a β oligomers but not the persistent
 414 impairment induced by low-molecular-weight oligomers. *J Neurosci* 33(23):9626-9634. doi:
 415 10.1523/JNEUROSCI.0482-13.2013.

416 Fu CL, Hsu LS, Liao YF, Hu MK (2016). New Hydroxyquinoline-Based Derivatives as Potent Modulators
 417 of Amyloid- β Aggregations. *Arch Pharm (Weinheim)* 349(5):327-341. doi: 10.1002/ardp.201500453.

418 Gomes LM, Vieira RP, Jones MR, Wang MC, Dyrager C, Souza-Fagundes EM et al. (2014). 8-
 419 Hydroxyquinoline Schiff-base compounds as antioxidants and modulators of copper-mediated A β peptide
 420 aggregation. *J Inorg Biochem* 139:106-116. doi: 10.1016/j.jinorgbio.2014.04.011.

421 Hauser-Davis RA, de Freitas LV, Cukierman DS, Cruz WS, Miotto MC, Landeira-Fernandez J et al.
 422 (2015). Disruption of zinc and copper interactions with A β (1-40) by a non-toxic, isoniazid-derived,
 423 hydrazone: a novel biometal homeostasis restoring agent in Alzheimer's disease therapy? *Metallomics*
 424 7:743-747. doi: 10.1039/c5mt00003c.

425 Hureau C (2012). Coordination of redox active metal ions to the amyloid precursor protein and to
 426 amyloid- β peptides involved in Alzheimer disease. Part 1: An overview. *Coordination Chemistry Reviews*
 427 256(19):2164-2174. doi: <https://doi.org/10.1016/j.ccr.2012.03.037>.

428 Jiang D, Li X, Liu L, Yagnik GB, Zhou F (2010). Reaction rates and mechanism of the ascorbic acid
 429 oxidation by molecular oxygen facilitated by Cu(II)-containing amyloid-beta complexes and aggregates.
 430 *J Phys Chem B* 114(14):4896-4903. doi: 10.1021/jp9095375.

431 Jürgensen S, Antonio LL, Mussi GE, Brito-Moreira J, Bomfim TR, De Felice FG et al. (2011). Activation
 432 of D1/D5 dopamine receptors protects neurons from synapse dysfunction induced by amyloid-beta
 433 oligomers. *J Biol Chem* 286(5):3270-3276. doi: 10.1074/jbc.M110.177790.

434 Kajal A, Bala S, Sharma N, Kamboj S, Saini V (2014). Therapeutic potential of hydrazones as anti-
 435 inflammatory agents. *Int J Med Chem* 2014:761030. doi: 10.1155/2014/761030.

436 Kupersmidt L, Amit T, Bar-Am O, Weinreb O, Youdim MB (2012). Multi-target, neuroprotective and
 437 neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and
 438 age-related alterations in mice. *Mol Neurobiol* 46(1):217-220. doi: 10.1007/s12035-012-8304-7.

439 Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M et al. (1998). Diffusible,
 440 nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. *Proc Natl*
 441 *Acad Sci U S A* 95(11):6448-6453.
 442 Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J et al. (2008). Safety, efficacy, and
 443 biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase
 444 IIa, double-blind, randomised, placebo-controlled trial. *Lancet Neurol* 7(9):779-786. doi: 10.1016/S1474-
 445 4422(08)70167-4.
 446 Laursen SE, Belknap JK (1986). Intracerebroventricular injections in mice. Some methodological
 447 refinements. *J Pharmacol Methods* 16(4):355-357.
 448 Ledo JH, Azevedo EP, Clarke JR, Ribeiro FC, Figueiredo CP, Foguel D et al. (2013). Amyloid- β
 449 oligomers link depressive-like behavior and cognitive deficits in mice. *Mol Psychiatry* 18(10):1053-1054.
 450 doi: 10.1038/mp.2012.168.
 451 Ledo JH, Azevedo EP, Beckman D, Ribeiro FC, Santos LE, Razolli DS et al. (2016). Cross Talk Between
 452 Brain Innate Immunity and Serotonin Signaling Underlies Depressive-Like Behavior Induced by
 453 Alzheimer's Amyloid- β Oligomers in Mice. *J Neurosci* 36(48):12106-12116. doi:
 454 10.1523/JNEUROSCI.1269-16.2016.
 455 Lister RG (1990). Ethologically-based animal models of anxiety disorders. *Pharmacol Ther* 46(3):321-
 456 340.
 457 Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF et al. (2013). TNF- α
 458 mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β -
 459 amyloid oligomers in mice and monkeys. *Cell Metab* 18(6):831-843. doi: 10.1016/j.cmet.2013.11.002.
 460 Lourenco MV, Frozza RL, de Freitas GB, Zhang H, Kincheski GC, Ribeiro FC et al. (2019). Exercise-
 461 linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models. *Nat Med*
 462 25(1):165-175. doi: 10.1038/s41591-018-0275-4.
 463 Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998). Copper, iron and zinc in
 464 Alzheimer's disease senile plaques. *J Neurol Sci* 158(1):47-52.
 465 Lu Y, Prudent M, Qiao L, Mendez MA, Girault HH (2010). Copper(I) and copper(II) binding to β -amyloid
 466 16 (A β 16) studied by electrospray ionization mass spectrometry. *Metallomics* 2(7):474-479. doi:
 467 10.1039/c004693k.
 468 Mancino AM, Hindo SS, Kochi A, Lim MH (2009). Effects of clioquinol on metal-triggered amyloid-
 469 beta aggregation revisited. *Inorg Chem* 48(20):9596-9598. doi: 10.1021/ic9014256.
 470 Mayeux R, Stern Y (2012). Epidemiology of Alzheimer disease. *Cold Spring Harb Perspect Med* 2(8).
 471 doi: 10.1101/cshperspect.a006239.
 472 Miura T, Suzuki K, Kohata N, Takeuchi H (2000). Metal binding modes of Alzheimer's amyloid beta-
 473 peptide in insoluble aggregates and soluble complexes. *Biochemistry* 39(23):7024-7031.
 474 Mucke L, Selkoe DJ (2012). Neurotoxicity of amyloid β -protein: synaptic and network dysfunction. *Cold*
 475 *Spring Harb Perspect Med* 2(7):a006338. doi: 10.1101/cshperspect.a006338.
 476 Prati F, Bergamini C, Fato R, Soukup O, Korabecny J, Andrisano V et al. (2016). Novel 8-
 477 Hydroxyquinoline Derivatives as Multitarget Compounds for the Treatment of Alzheimer's Disease.
 478 *ChemMedChem* 11(12):1284-1295. doi: 10.1002/cmdc.201600014.
 479 Rodgers RJ, Dalvi A (1997). Anxiety, defence and the elevated plus-maze. *Neurosci Biobehav Rev*
 480 21(6):801-810. doi: 10.1016/s0149-7634(96)00058-9.
 481 Ryan TM, Roberts BR, McColl G, Hare DJ, Doble PA, Li QX et al. (2015). Stabilization of nontoxic A β -
 482 oligomers: insights into the mechanism of action of hydroxyquinolines in Alzheimer's disease. *J Neurosci*
 483 35(7):2871-2884. doi: 10.1523/JNEUROSCI.2912-14.2015.
 484 Salkovic-Petrisic M, Knezovic A, Osmanovic-Barilar J, Smailovic U, Trkulja V, Riederer P et al. (2015).
 485 Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer's disease. *Life Sci*
 486 136:108-119. doi: 10.1016/j.lfs.2015.06.026.
 487 Sampson EL, Jenagaratnam L, McShane R (2012). Metal protein attenuating compounds for the treatment
 488 of Alzheimer's dementia. *Cochrane Database Syst Rev* 5:CD005380. doi:
 489 10.1002/14651858.CD005380.pub4.

490 Saraiva LM, Seixas da Silva GS, Galina A, da-Silva WS, Klein WL, Ferreira ST et al. (2010). Amyloid-
 491 β triggers the release of neuronal hexokinase 1 from mitochondria. PLoS One 5(12):e15230. doi:
 492 10.1371/journal.pone.0015230.
 493 Savelieff MG, Nam G, Kang J, Lee HJ, Lee M, Lim MH (2018). Development of Multifunctional
 494 Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and
 495 Amyotrophic Lateral Sclerosis in the Last Decade. Chem Rev. doi: 10.1021/acs.chemrev.8b00138.
 496 Savini L, Chiasserini L, Travagli V, Pellerano C, Novellino E, Cosentino S et al. (2004). New alpha-(N)-
 497 heterocyclchydrazones: evaluation of anticancer, anti-HIV and antimicrobial activity. Eur J Med Chem
 498 39(2):113-122. doi: 10.1016/j.ejmech.2003.09.012.
 499 Scott LE, Orvig C (2009). Medicinal inorganic chemistry approaches to passivation and removal of
 500 aberrant metal ions in disease. Chem Rev 109(10):4885-4910. doi: 10.1021/cr9000176.
 501 Sebollela A, Freitas-Correa L, Oliveira FF, Paula-Lima AC, Saraiva LM, Martins SM et al. (2012).
 502 Amyloid- β oligomers induce differential gene expression in adult human brain slices. J Biol Chem
 503 287(10):7436-7445. doi: 10.1074/jbc.M111.298471.
 504 Selkoe DJ, Hardy J (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med
 505 8(6):595-608. doi: 10.15252/emmm.201606210.
 506 Silva AG, Zapata-Sudo G, Kummerle AE, Fraga CA, Barreiro EJ, Sudo RT (2005). Synthesis and
 507 vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues. Bioorg
 508 Med Chem 13(10):3431-3437. doi: 10.1016/j.bmc.2005.03.003.
 509 Su T, Zhang T, Xie S, Yan J, Wu Y, Li X et al. (2016). Discovery of novel PDE9 inhibitors capable of
 510 inhibiting A β aggregation as potential candidates for the treatment of Alzheimer's disease. Sci Rep
 511 6:21826. doi: 10.1038/srep21826.
 512 Unzeta M, Esteban G, Bolea I, Fogel WA, Ramsay RR, Youdim MB et al. (2016). Multi-Target Directed
 513 Donepezil-Like Ligands for Alzheimer's Disease. Front Neurosci 10:205. doi: 10.3389/fnins.2016.00205.
 514 Vicini P, Incerti M, Doytchinova IA, La Colla P, Busonera B, Loddo R (2006). Synthesis and
 515 antiproliferative activity of benzo[d]isothiazole hydrazones. Eur J Med Chem 41(5):624-632. doi:
 516 10.1016/j.ejmech.2006.01.010.
 517 Villemagne VL, Rowe CC, Barnham KJ, Cherny R, Woodward M, Bozinosvski S et al. (2017). A
 518 randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in
 519 Alzheimer's disease: The PBT2-204 IMAGINE study. Alzheimers Dement (N Y) 3(4):622-635. doi:
 520 10.1016/j.trci.2017.10.001.
 521 Wang Z, Wang Y, Wang B, Li W, Huang L, Li X (2015). Design, Synthesis, and Evaluation of Orally
 522 Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in
 523 a Rat Model of Neurodegeneration in Alzheimer's Disease. J Med Chem 58(21):8616-8637. doi:
 524 10.1021/acs.jmedchem.5b01222.
 525 Yang X, Cai P, Liu Q, Wu J, Yin Y, Wang X et al. (2018). Novel 8-hydroxyquinoline derivatives targeting
 526 β -amyloid aggregation, metal chelation and oxidative stress against Alzheimer's disease. Bioorg Med
 527 Chem 26(12):3191-3201. doi: 10.1016/j.bmc.2018.04.043.

528

Figure 1. Chemical structure of the aroylhydrazone INHHQ.

Figure 2. **INHHQ does not induce fear/anxiety behavior or affect locomotor activity or memory in mice.** Fear/anxiety behavior assessed in the elevated plus-maze (a-d). Testing was performed 1 h (a, b) or 4 h (c, d) after administration of INHHQ (i.p.) at the indicated doses. Bars represent means $\pm$ SEM ($N= 8-10$ mice per group). Locomotor activity (e, g) and anxiety behavior (f, h) assessed in the OF test. Testing was performed 1 h (e, f) or 4 h (g, h) after administration of INHHQ. Bars represent means $\pm$ SEM ($N= 8-16$ mice per group). Effect of INHHQ on novel object recognition (NOR) memory (i-q). INHHQ was administered i.p. at the indicated doses 1 h (i, l, and o), 4 h (j, m, and p) or 24 h (k, n, and q) before the NOR test. Data are reported as percentage of exploration time of familiar and novel objects (i-k), discrimination index (l-n), and total exploration time (o-q). White bars refer to novel object exploration, and gray bars refer to familiar object exploration, respectively, and correspond to means $\pm$ SEM ($N= 8-14$ mice per group). Dashed lines indicate chance value (50%). * $p < 0.05$, one-sample Student's t -test comparing to the fixed value of 50%.

544

545

546 Figure 3. INHHQ prevents memory deficit induced by A β Os. A β Os (10 pmol) were infused i.c.v. in mice 1 h after
 547 i.p. treatment with INHHQ (1 mg kg⁻¹). For assessment of STM, the retention test was performed 1 h after training,
 548 whereas for assessment of LTM the retention test was performed 24 h after training. Tests for STM were performed
 549 24 h (a, d, and g) or 7 days (c, f, and i) after infusion of A β Os. Tests for LTM were performed 48 h after infusion
 550 of A β Os (b, e, and h). Data are reported as discrimination index (a-c), as percentage of exploration time of familiar
 551 and novel objects (d-f) and as total exploration time (g-i). White bars refer to novel object exploration, and gray
 552 bars refer to familiar object exploration, respectively, and correspond to means $\pm$ SEM (N= 9-10 mice per group).
 553 Dashed lines indicate the chance value (50%). **A** $p < 0.05$, two-way ANOVA followed by Bonferroni's *post-hoc*
 554 *test comparing with vehicle-vehicle group*. **B** $p < 0.05$, two-way ANOVA followed by Bonferroni's *post-hoc*
 555 *test comparing with vehicle-A β Os group*. Results are from one representative experiment from a total of three
 556 independent trials that yielded similar results. * $p < 0.05$, one-sample Student's *t*-test comparing to the fixed value
 557 of 50%.

560 Figure 4. **Cu(A β)-induced ascorbate consumption.** (a) Plots showing ascorbate consumption rate for: (i) Cu(A β),
561 (ii) Cu(A β) + 1 equivalent INHHQ, (iii) Cu,Zn(A β) + 1 equivalent INHHQ, (iv) Cu(A β) + 5 equivalents INHHQ.
562 The sharp increase observed after INHHQ addition is due to the intrinsic absorbance of the resulting Cu(INHHQ)
563 complex. Rates of ascorbate consumption induced by Cu(A β) were measured in the presence of increasing INHHQ
564 concentrations (b). (c) Ascorbate consumption induced by Cu,Zn:A β with or without one equivalent of INHHQ.

565